Comparative genomic hybridization detects many recurrent imbalances in central nervous system primitive neuroectodermal tumours in children

por Avet-Loiseau, H, Vénuat, A-M, Terrier-Lacombe, M-J, Lellouch-Tubiana, A, Zerah, M, Vassal, G
Publicado 1999

Prognostic utility of intact immunoglobulin Ig′κ/Ig′λ ratios in multiple myeloma patients

por Bradwell, A, Harding, S, Fourrier, N, Mathiot, C, Attal, M, Moreau, P, Harousseau, J-L, Avet-Loiseau, H
Publicado 2013

Difficulties in immunofixation analysis: a concordance study on the IFM 2007-02 trial

por Caillon, H, Dejoie, T, Le Loupp, A-G, Azoulay-Fauconnier, C, Masson, D, Moreau, P, Denis, M, Avet-Loiseau, H
Publicado 2013

Heavy+light chain monitoring correlates with clinical outcome in multiple myeloma patients

por Michallet, M, Chapuis-Cellier, C, Dejoie, T, Lombard, C, Caillon, H, Sobh, M, Moreau, P, Attal, M, Avet-Loiseau, H
Publicado 2018

Expressed fusion gene landscape and its impact in multiple myeloma

por Cleynen, A., Szalat, R., Kemal Samur, M., Robiou du Pont, S., Buisson, L., Boyle, E., Chretien, M. L., Anderson, K., Minvielle, S., Moreau, P., Attal, M., Parmigiani, G., Corre, J., Munshi, N., Avet-Loiseau, H.
Publicado 2017

A DNA target-enrichment approach to detect mutations, copy number changes and immunoglobulin translocations in multiple myeloma

por Bolli, N, Li, Y, Sathiaseelan, V, Raine, K, Jones, D, Ganly, P, Cocito, F, Bignell, G, Chapman, M A, Sperling, A S, Anderson, K C, Avet-Loiseau, H, Minvielle, S, Campbell, P J, Munshi, N C
Publicado 2016

Absence of mutations in cereblon (CRBN) and DNA damage-binding protein 1 (DDB1) genes and significance for IMiD therapy

por Thakurta, A, Gandhi, A K, Waldman, M F, Bjorklund, C, Ning, Y, Mendy, D, Schafer, P, Lopez-Girona, A, Lentzsch, S, Schey, S A, Calle, Y, Chelliah, R, Orlowski, R Z, Madan, A, Avet-Loiseau, H, Chopra, R
Publicado 2014

Nucleotide excision repair is a potential therapeutic target in multiple myeloma

por Szalat, R, Samur, M K, Fulciniti, M, Lopez, M, Nanjappa, P, Cleynen, A, Wen, K, Kumar, S, Perini, T, Calkins, A S, Reznichenko, E, Chauhan, D, Tai, Y-T, Shammas, M A, Anderson, K C, Fermand, J-P, Arnulf, B, Avet-Loiseau, H, Lazaro, J-B, Munshi, N C
Publicado 2018

Summary version of the Standards, Options and Recommendations for the management of adult patients with intracranial glioma (2002)

por Frappaz, D, Chinot, O, Bataillard, A, Ben Hassel, M, Capelle, L, Chanalet, S, Chatel, M, Figarella-Branger, D, Guegan, Y, Guyotat, J, Hoang-Xuan, K, Jouanneau, E, Keime-Guibert, F, Laforêt, C, Linassier, C, Loiseau, H, Maire, J P, Menei, P, Rousmans, S, Sanson, M, Sunyach, M P
Publicado 2003

B05 PLASMA CELL LEUKEMIA-LIKE STATUS HAS INDEPENDENT PROGNOSTIC VALUE IN THE CONTEXT OF THE SECOND REVISION OF THE INTERNATIONAL STAGING SYSTEM

por Hofste op Bruinink, D., Kuiper, R., van Duin, M., Cupedo, T., van der Velden, V., Hoogenboezem, R., van der Holt, B., Beverloo, B., Valent, E., Vermeulen, M., D’Agostino, M., Gay, F., Broijl, A., Avet-Loiseau, H., Munshi, N., Musto, P., Moreau, P., Zweegman, S., van de Donk, N., Sonneveld, P.
Publicado 2023

Biological and prognostic impact of APOBEC-induced mutations in the spectrum of plasma cell dyscrasias and multiple myeloma cell lines

por Maura, F, Petljak, M, Lionetti, M, Cifola, I, Liang, W, Pinatel, E, Alexandrov, L B, Fullam, A, Martincorena, I, Dawson, K J, Angelopoulos, N, Samur, M K, Szalat, R, Zamora, J, Tarpey, P, Davies, H, Corradini, P, Anderson, K C, Minvielle, S, Neri, A, Avet-Loiseau, H, Keats, J, Campbell, P J, Munshi, N C, Bolli, N
Publicado 2018

P872: DEL(1P32) REMAINS A POWERFUL PROGNOSTIC FACTOR IN A LARGE COHORT OF NDMM PATIENTS: AN UPDATE

por Schavgoulidze, A., Perrot, A., Cazaubiel, T., Leleu, X., Manier, S., Buisson, L., Maheo, S., Do Souto Ferreira, L., Lannes, R., Pavageau, L., Hulin, C., Marolleau, J.-P., Voillat, L., Belhadj, K., Divoux, M., Slama, B., Brechignac, S., Macro, M., Stoppa, A.-M., Sanhes, L., Orsini-Piocelle, F., Fontan, J., Chretien, M.-L., Demarquette, H., Mohty, M., Avet-Loiseau, H., Corre, J.
Publicado 2022

P891: IXAZOMIB, POMALIDOMIDE AND DEXAMETHASONE (IXPD) IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM) CHARACTERIZED WITH HIGH-RISK CYTOGENETICS. IFM 2014-01

por Bobin, A., Manier, S., De Keizer, J., Karlin, L., Perrot, A., Hulin, C., Caillot, D., Mariette, C., Lenain, P., Richez, V., Tiab, M., Touzeau, C., Jaccard, A., Decaux, O., Araujo, C., Belhadj, K., Benboubker, L., Déal, C., Macro, M., Vincent, L., Arnulf, B., Bareau, B., Braun, T., Calmettes, C., mamoun, D., Zerazhi, H., Demarquette, H., Feugier, P., Fohrer-sonntag, C., Godet, S., Petillon, M.-O., Avet-Loiseau, H., Leleu, X.
Publicado 2022